Search

everythinglearnresearchcommunity

for

Search:↓

The user shared their 2 1/2 years of progress treating hair loss with finasteride, minoxidil, and dermarolling, noting a slight improvement from RU58841 and a recent addition of oral minoxidil. They varied their finasteride dosage, used both topical and oral minoxidil, and saw better results with short hair, hoping for further improvement.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.

Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.

A 22-year-old male is experiencing worsening hair loss despite taking 0.25mg oral finasteride and 2.5mg oral minoxidil daily since July. He is considering seeking a second opinion as his dermatologist refuses to increase the finasteride dosage, and he does not use dermarolling or vitamins.

A user reported that after nearly 2 years of using finasteride with initial hair regrowth, their hairline worsened around day 570 and has not improved significantly since. They are considering switching to dutasteride or changing finasteride brands, while responders suggest the user may not actually be experiencing hair loss and might benefit from professional help.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

A user's progress with treating their hair loss using Minoxidil, finasteride, and dermarolling after two months of treatment; the conversation includes other users' observations of improvement and encouragement.